Brokerages predict that Stryker Co. (NYSE:SYK) will report $2.97 billion in sales for the current fiscal quarter, according to Zacks. Ten analysts have issued estimates for Stryker’s earnings. The highest sales estimate is $3 billion and the lowest is $2.95 billion. Stryker posted sales of $2.84 billion in the same quarter last year, which would indicate a positive year over year growth rate of 4.6%. The firm is expected to issue its next earnings report on Thursday, July 20th.

On average, analysts expect that Stryker will report full-year sales of $2.97 billion for the current financial year, with estimates ranging from $12.16 billion to $12.25 billion. For the next year, analysts expect that the business will post sales of $12.96 billion per share, with estimates ranging from $12.76 billion to $13.11 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Stryker.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.90 billion. Stryker had a net margin of 14.54% and a return on equity of 23.86%. The business’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.24 earnings per share.

A number of brokerages recently issued reports on SYK. Goldman Sachs Group Inc began coverage on Stryker in a research note on Tuesday, May 16th. They issued a “neutral” rating and a $129.00 price objective on the stock. Deutsche Bank AG reiterated a “buy” rating and set a $148.00 price target (up from $135.00) on shares of Stryker in a research report on Saturday, April 29th. Barclays PLC reiterated a “sell” rating and set a $133.00 price target on shares of Stryker in a research report on Thursday, April 27th. Cowen and Company set a $150.00 price target on Stryker and gave the company an “outperform” rating in a research report on Wednesday, April 26th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $140.00 price target (up from $135.00) on shares of Stryker in a research report on Wednesday, April 26th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. Stryker presently has a consensus rating of “Hold” and a consensus price target of $134.81.

Shares of Stryker (NYSE:SYK) opened at 141.27 on Friday. The firm’s 50-day moving average is $134.70 and its 200-day moving average is $125.59. The firm has a market capitalization of $52.80 billion, a P/E ratio of 31.75 and a beta of 0.80. Stryker has a 52 week low of $106.48 and a 52 week high of $141.59.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 31st. Shareholders of record on Friday, June 30th will be issued a $0.425 dividend. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.20%. Stryker’s dividend payout ratio (DPR) is 39.08%.

In other Stryker news, insider Timothy J. Scannell sold 13,322 shares of the stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $135.89, for a total value of $1,810,326.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.80% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the stock. HM Payson & Co. increased its position in shares of Stryker by 13.0% in the first quarter. HM Payson & Co. now owns 4,116 shares of the medical technology company’s stock valued at $542,000 after buying an additional 475 shares during the last quarter. Pointe Capital Management LLC bought a new position in shares of Stryker during the first quarter valued at $271,000. Achmea Investment Management B.V. bought a new position in shares of Stryker during the first quarter valued at $2,307,000. Bank of Nova Scotia increased its position in shares of Stryker by 913.0% in the first quarter. Bank of Nova Scotia now owns 70,790 shares of the medical technology company’s stock valued at $9,319,000 after buying an additional 63,802 shares during the last quarter. Finally, Northern Oak Wealth Management Inc. increased its position in shares of Stryker by 38.1% in the first quarter. Northern Oak Wealth Management Inc. now owns 4,280 shares of the medical technology company’s stock valued at $563,000 after buying an additional 1,180 shares during the last quarter. Hedge funds and other institutional investors own 75.29% of the company’s stock.

WARNING: “Brokerages Expect Stryker Co. (SYK) Will Announce Quarterly Sales of $2.97 Billion” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/05/27/brokerages-expect-stryker-co-syk-will-announce-quarterly-sales-of-2-97-billion.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

12 Month Chart for NYSE:SYK

Get a free copy of the Zacks research report on Stryker (SYK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.